tag/yeas/

Breaking Biology Technology:Oxford BioTherapeutics Appoints Michael Moore as Chairman 2 Oxford BioTherapeutics Appoints Michael Moore as Chairman 3 Oxford BioTherapeutics Appoints Michael Moore as Chairman 4 Repligen Announces Conference Call to Discuss Phase 3 Clinical Trial Results of RG1068 in MRI Imaging of the Pancreas 2 Repligen Announces Conference Call to Discuss Phase 3 Clinical Trial Results of RG1068 in MRI Imaging of the Pancreas 3 Microfluidics Chairman James N. Little, Ph.D., Announces Retirement from Board of Directors 2 Microfluidics Chairman James N. Little, Ph.D., Announces Retirement from Board of Directors 3 Reportlinker Adds Biotechnology Instrumentation - International Market Trends 2 Reportlinker Adds Biotechnology Instrumentation - International Market Trends 3 Reportlinker Adds Biotechnology Instrumentation - International Market Trends 4 Reportlinker Adds Biotechnology Instrumentation - International Market Trends 5 Reportlinker Adds Biotechnology Instrumentation - International Market Trends 6 Reportlinker Adds Biotechnology Instrumentation - International Market Trends 7

[0] Oxford BioTherapeutics Appoints Michael Moore as Chairman [0] Repligen Announces Conference Call to Discuss Phase 3 Clinical Trial Results of RG1068 in MRI Imaging of the Pancreas [0] Microfluidics Chairman James N. Little, Ph.D., Announces Retirement from Board of Directors [0] Reportlinker Adds Biotechnology Instrumentation - International Market Trends

Breaking Medicine Technology:Perrigo Confirms Filing for Generic Version of Clobex(R) Spray and Announcement of Lawsuit by Galderma and Dermalogix 2 Perrigo Confirms Filing for Generic Version of Clobex(R) Spray and Announcement of Lawsuit by Galderma and Dermalogix 3 Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 2 Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 3 Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 4 Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 5 Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 6 BioCryst Pharmaceuticals Elects Charles A. Sanders to its Board of Directors 2 BioCryst Pharmaceuticals Elects Charles A. Sanders to its Board of Directors 3 BioCryst Pharmaceuticals Elects Charles A. Sanders to its Board of Directors 4 Hispanic Workers Ages 50+ May Help Employers Solve Potential Future Labor Shortages 48195 1 Hispanic Workers Ages 50+ May Help Employers Solve Potential Future Labor Shortages 48195 2 Hispanic Workers Ages 50+ May Help Employers Solve Potential Future Labor Shortages 48195 3 Robot Speaks Many Languages Improves Pharmacy Patient Outcomes 48192 1 Robot Speaks Many Languages Improves Pharmacy Patient Outcomes 48192 2 Medical Home Pilot Initiatives Continue to Expand Nationwide 48189 1 Medical Home Pilot Initiatives Continue to Expand Nationwide 48189 2 Medical Home Pilot Initiatives Continue to Expand Nationwide 48189 3

[0] Perrigo Confirms Filing for Generic Version of Clobex(R) Spray and Announcement of Lawsuit by Galderma and Dermalogix [0] Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase [0] BioCryst Pharmaceuticals Elects Charles A. Sanders to its Board of Directors